Invivyd, Inc. (IVVD)
NASDAQ: IVVD · Real-Time Price · USD
1.140
+0.142 (14.29%)
At close: Sep 5, 2025, 4:00 PM
1.120
-0.020 (-1.75%)
After-hours: Sep 5, 2025, 7:59 PM EDT

Company Description

Invivyd, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States.

The company’s pipeline includes PEMGARDA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate, which is in preclinical studies for the prevention or treatment of COVID-19; and Adintrevimab that is in phase 2/3 clinical trials for the prevention and treatment of COVID-19.

It also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. The company has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies.

The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022.

Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

Invivyd, Inc.
Invivyd logo
CountryUnited States
Founded2020
IPO DateAug 6, 2021
IndustryBiotechnology
SectorHealthcare
Employees100
CEOWilliam Duke

Contact Details

Address:
1601 Trapelo Road, Suite 178
Waltham, Massachusetts 02451
United States
Phone781 819 0080
Websiteinvivyd.com

Stock Details

Ticker SymbolIVVD
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$17.00
CIK Code0001832038
CUSIP Number00534A102
ISIN NumberUS00534A1025
Employer ID85-1403134
SIC Code2836

Key Executives

NamePosition
William E. Duke Jr., M.B.A.Chief Financial Officer, Principal Accounting Officer and Principal Executive Officer
Julie Green M.B.A.Chief Human Resources Officer and Head of Communications
Timothy LeeChief Commercial Officer
Dr. Robert D. Allen Ph.D.Chief Scientific Officer
Scott YoungSenior Vice President of Investor Relations and Corporate Communications
Jill Andersen J.D.Chief Legal Officer and Corporate Secretary
Dr. Mark A. Wingertzahn Ph.D.Senior Vice President of Clinical Development and Medical Affairs

Latest SEC Filings

DateTypeTitle
Aug 29, 2025SCHEDULE 13GFiling
Aug 27, 2025SCHEDULE 13GFiling
Aug 26, 2025SCHEDULE 13D/AFiling
Aug 22, 20258-KCurrent Report
Aug 22, 2025424B5Filing
Aug 20, 2025FWPFree Writing Prospectus
Aug 20, 2025424B5Filing
Aug 18, 2025144Filing
Aug 18, 2025144Filing
Aug 18, 2025144Filing